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Summary.-The effects of adriamycin (Adr) on the solid-tumour model, hepatoma
3924A, and on critical organs of the host, were determined at intervals after single
injections of 60 mg/M2 of the agent. A reduced rate of tumour growth was evident 4
days after treatment, continued to Day 11, and then returned to rates comparable to
control values. On Day 11 tumour volumes of treated animals were 38% of control.
During the period of reduced growth, 3H-TdR incorporation into tumour DNA and
percentage labelled tumour cells were less than control values. DNA concentration
in tumour was not affected by drug treatment, which differs from observations made
in other studies employing 5-fluorouracil (FU). No evidence of significantly increased
necrosis or fibrosis of the tumour was found after Adr. The Adr treatment caused
loss of 60% of the tibial marrow by Day 4, as measured by total DNA content.
Marrow DNA recovered to control levels between Days 7 and 11. Incorporation of
3H-TdR into heart DNA was reduced more than400/o during the first week after Adr
treatment; enhanced incorporation was observed on Day 11, and control levels were
attained by Day 17. No significant pathological evidence of cardiac toxicity was
found 2-21 days after Adr but degeneration of myocardial cells and oedema was
prominent at 14 weeks.
THE kinetics ofrecovery for tumour and
host organs after treatment with 5-fluoro-
uracil (FU) have recently been determined
for the experimental solid-tumour system,
hepatoma 3924A (Kovacs et al., 1975;
Hopkins et al., 1976; Looney et al., 1976)
and these data have been used in the
design of an effective chemotherapy-
radiotherapy combination for this tumour
(Looney et al., 1977). The present report
summarizes data obtained for hepatoma
3924A and its host the ACI rat after
treatment with adriamycin (Adr), a
relatively new chemotherapeutic agent
which is effective against a wide range of
human neoplasms (Carter, 1975). Evalu-
ation of the effects of Adr has included
determinations of changes in tumour
volume, changes in DNA content and
3H-TdR incorporation for marrow, intes-
tinal mucosa, heart and tumour, tumour
TdR labelling indices and pathological
evaluations of tumour and host organs.
Haematological data were obtained for
peripheral blood and, in other studies,
liver-function tests were performed, to
obtain as much clinically relevant infor-
mation as possible in this evaluation of
the effects ofAdr on both the solid tumour
and its host.
METHODS
Animals and tumours. Inbred female
ACI-strain rats (Laboratory Supply Co.,
Indianapolis, Ind. and Mammalian Genetics
and Animal Production Section, National
Cancer Institute) usually weighing 120-140 g
were used. Tumour-bearing animals had s.c.
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transplants of Morris hepatoma 3924A. The
rats were caged individually in an air-con-
ditioned room lighted from 8 a.m. to 8 p.m.
and provided rat chow (Charles River
Laboratories, Wilmington, Mass.) and water
ad libitum.
Drug.-Adriamycin (Adr, synonym doxo-
rubicin) was supplied by the Drug Synthesis
& Chemistry Branch, Division of Cancer
Treatment, National Cancer Institute. It wAas
dissolved in 0.90o NaCl and usually admin-
istered by i.p. injection of doses of 60 mg/M2
(10 mg/kg). Where i.v. or s.c. injections or
differing doses of drug wAere given, these are
indicated in the text.
Experimental.-At various times after
injection of 60 mg/M2 Adr and 1 h prior to
killing, groups of 3 rats each were injected
i.p. with 50,Ci thymidine-(methyl)-3H (sp.
act. 3 Ci/mmol). At killing, blood for WBC,
haematocrit and haemoglobin determinations
was taken by cardiac puncture under ether
anaesthesia. The tumour, tibia, heart and a
4 cm length of intestine immediately distal
to the pylorus were removed for biochemical
and histologic evaluations. Tissue specimens
were routinely fixed in neutral formalin,
embedded in paraffin, sectioned, and stained
with haematoxylin and eosin. In addition,
Masson stain was used for tumour. Auto-
radiographs were prepared with Kodak
NTB-2 after Feulgen staining. Slides were
exposed for 3 Mweeks, then developed with
Kodak D-19.
The marrow Nas aspirated from the tibia
with cold 0.90o NaCl. The 4 cm length of
intestine was slit longitudinally and the
mucosa stripped from the underlying muscle.
Tumour and heart were chilled in cold 0-90
NaCl, weighed, and portions taken for deter-
mination of DNA and 3H counts in the DNA
fractions. RNA was eliminated from all
samples by alkaline hydrolysis followed by
washing with cold 10% trichloroacetic acid.
DNA was extracted by heating at 90°C for
20 min with 500 trichloroacetic acid and was
measured by the method of Burton (1956).
Calfthymus DNA (Sigma, St Louis, MO) was
the standard. Radioactivity in the nucleic
acid extracts was measured on a Beckman
liquid scintillation spectrophotometer with
external standardization.
Acute animal survival was determined 21
days after Adr injection or, if more than one
dose was given, 21 days after the final
injection.
RESULTS
Changes in tumour growth and kinetics
Treatment of rats bearing hepatoma
3924A with 60 mg/M2 Adr as a single dose
resulted in a reduced rate of growth for
the tumour (Fig. 1) which was evident 4
days after treatment. The rate of tumour
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Fio. I. Mean tumour volumes for hepatoma
3924A after Adr treatment. Each point is
the mean (±s.e.) for 6 treated rats or 8
control rats. *, 60 mg/M2 Adr; 0, control.
growth was reduced until about Day 11
after treatment, at which time the rate of
growth for treated tumours returned to
control rates. Tumour volumes were 38%
of control at that time. The time necessary
to reach an average tumour volume of 5
cm3 from initial volumes of 0 27 cm3 was
increased from 9 days for control to 14
days. During the period of reduced
tumour growth, 4-11 days after treatment,
incorporation of 3H-TdR into tumour
DNA was inhibited relative to untreated
tumours (Fig. 2) and percentage labelled
interphase cells determined by autoradio-
graphy were similarly reduced. The con-
centration of DNA (mg DNA/g oftumour)
was not altered by drug treatment (Fig.
2). Tumour sections stained with haema-
toxylin and eosin showed no effect of the
drug on tumour histology or necrosis.
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FIG. 2. Effect of Adr on 3H-TdR incorpor-
ation into DNA, % labelled cells, and
DNA concentration of hepatoma 3924A.
Each point is the mean (±s.e.) for 3 rats,
except 2 rats where standard error is not
indicated. 0, 60 mg/M2 Adr; 0, control.
Masson stain also did not indicate any
significant increase of fibrosis within the
tumour.
Marrow
There was loss of marrow after adminis-
tration of Adr, amounting to -...60% by
Day 4 as measured by mg DNA per tibial
marrow (Fig. 3). Total DNA per tibial
marrow is proportional to the total number
of nucleated cells present at this marrow
site, therefore it can be used as an index
of marrow cellularity. Recovery to un-
treated control levels took place between
Days 7 and 11. For rats with tumours the
increases in marrow DNA content for the
untreated rats, and after Day 14 for the
treated rats, are the result of an increased
granulocytopoiesis associated with the
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FIG. 3. Tibial marrow DNA after Adr
treatment of ACI rats with and without
tumours. Open symbols, no drug. Closed
symbols, 60 mg/M2 Adr. Squares, rats
without tumours; Circles, rats with hepa-
toma 3924A.
growth of hepatoma 3924A (Hopkins et
al., 1977). Neither the magnitude of the
loss of marrow after Adr nor the timing of
the recovery was appreciably affected by
the presence of the tumour. Incorporation
of 3H-TdR into marrow DNA was deter-
mined at intervals after drug administra-
tion, and is expressed in Fig. 4 (top) as
d/min/mg DNA. The large apparent
increases in specific activity of marrow
DNA 2 to 4 days after Adr, possibly
result from loss of marrow DNA (Fig. 3)
rather than from increased DNA syn-
thesis. Expressed as d/min/tibia (Fig. 4,
bottom), 3H-TdR incorporation is con-
stant but depressed relative to control
values, during the period of time that
marrow is being lost from the tibia. It is
remarkable that recovery of marrow DNA
content occurs without an increase in
3H-precursor incorporation. This differs
from the situation observed after treat-
ment of rats with FU (Hopkins et al.,
1976). At longer times after 60 mg/M2 Adr
both DNA content and specific activity of
the DNA were depressed 25% or more
relative to control (Table I).
Haematological data
Changes in WBC concentrations in
peripheral blood after the administration
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FIG. 4. 311-TdR incorporation into tibial
marrow DNA after Adr treatment, expres-
sed as d/min/mg DNA and as d/min/tibial
marrow. 0, 60 mg/M2 Adr; 0, control.
ofAdr to animals with tumours are shown
in Table II. WBC concentrations were
depressed 30-40% below initial control
values on Days 4, 7 and 11 after treatment.
Hepatoma 3924A stimulates granulocyto-
poiesis in the ACI rat (Hopkins etal., 1977)
accounting for the increasing WBC values
for the controls and for treated animals
after Day 11. Haemoglobin and haemato-
crit values are not shown, but were similar
for drug-treated and control rats, with the
greatest difference, observed on Day 7,
being only 18%.
Intestinal mucosa
DNA measurements revealed that the
cellularity of the intestinal mucosa after
i.p. injection of Adr was -20% below
control level for 4 days, (Fig. 5A). Incor-
poration of 3H-TdR into DNA was less
than control at 24 h after treatment, then
increased markedly to more than twice
control values on Day 4 (Fig. 5B). DNA
accumulated after the episode ofincreased
3H-TdR incorporation, and remained
elevated for the duration of the experi-
TABLE I.-Effect of Route of Administration of 60 mg/M2 Adr on 3H-TdR Incorporation
and DNA Content of Tibial Marrow, Heart and Intestinal Mucosa of Rats
Post-treatment
interval
(weeks)
3
8
12
3
8
12
3
8
12
3
8
12
3
8
12
Route of administration
1.v. s.c.
mg DNA/Tibial Marrow
0-40±0-06 0-42±0-02
0-38±0-06 0-28±0-01
0-31±0-02 0-30±0-03
d/min/mg Marrow DNA x 10-5
1-20 (2 rats) 1-97±0-55
1-26±0-05 1-48±0-07
0-91±0-04 1-41±0-34
mg DNA/4 cm Intestinal Mucosa
1-14±0-32 1-39±0-20
1-35±0-11 1-44±0-08
1-35±0-10 1-26±0-09
l.p.
0-50 (2 rats)
0-49±0-12
dead
1-98 (2 rats)
0-78±0-22
dead
1 -62 (2 rats)
1-70±0-45
dead
d/min/mg Mucosal DNA x 10-5
2-16 (2 rats) 3-45±0-62 3-80 (2 rats)
3-20±0-31 2-70±0-32 1-81±0-70
2-15±0-15 2-98±0-49 dead
d/min/mg Heart DNA x 10-4
1-77±0-15 1-65±0-31 1-80±0-15
0-49±0-08 1-60±0-30 1-62+0-66
1-36±0-29 1-02±0-31 dead
3 animals in each group unless otherwise stated.
Figures are means ± s.e.
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0-42±0-05
0-38±0-02
0-39±0-04
2-02±0-08
2-03± -011
2-01±0-15
1-42+0- 11
1-39±0-06
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TABLE II.-Changes in Peripheral WBC
Counts of ACI Rats with Hepatoma
3924A after Adr Administration
Time WBC countS/mm3
after Adr - A A
(days) Controls Treated
2 46254 463* 4800 (2 rats)
4 4600± 183 2833± 219
7 5275+ 397 3050 (2 rats)
9 7350± 796 5500± 643
11 6775± 912 3333± 384
13 7725± 364 6600± 929
15 8550±1041 7567±1613
17 9775± 669 8667± 437
21 93674- 484 7033±i1073
* Mean±s.e.-4 animals in each
and 3 animals in each Treated
otherwise stated).
Control Group
Group (unless
ment. However, the increased cellularity
of the intestinal mucosa after Adr treat-
ment appears to be related to the i.p.
route of administration. I.v. or s.c.
injections do not increase the DNA
content of the mucosa at 3, 8 or 12 weeks
after the drug (Table I).
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Heart
In heart, inhibition of 3H-TdR incor-
poration into DNA, by more than 40%,
was observed during the first week after
Adr was given (Fig. 6A). Enhanced incor-
poration was seen on Day 11, with return
to control levels by Day 17. Average heart
DNA content for drug-treated rats was
not different from control, after adjusting
for differences in animal weights (Fig. 6B).
Rats injected with 60 mg/M2 Adr by i.v.,
s.c., or i.p. routes and killed 3, 8 or 12
weeks later, often showed increased 3H-
TdR incorporation in heart DNA (Table
I). Incorporation was about twice that of
control rats at these times.
Foci of myocardial-cell degeneration
accompanied by convergence of phago-
cytic cells were occasionally seen in the
histologic preparations from rats treated
2 to 21 days earlier with 60 mg/M2 Adr,
and in control animals as well. However,
in rats surviving this drug treatment for
14 weeks, the incidence of these patho-
logical changes was much increased.
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FiG. 5. Effect of Adr on intestinal mucosa.
A. DNA content. B. TdR incorporation.
0, 60 mg/M2 Adr; 0, control.
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FIG. 6. Effect of Adr on heart DNA.
A. TdR incorporation into heart DNA.
B. Mean DNA content ofheart. Solid sym-
bols, 60 mg/M2 Adr; open symbols, control.
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*-4- 3x45 or 3X30 mg/m2
Interval Between Doses (Days)
Fic.. 7.-Survival of rats given multiple
injections of Adr as a fuinction of the
interval between injections. Each group
contained 10 rats.
Oedemna and degeneration of myocardial
fibres were prominent. Some intracyto-
plasmic vacuoles were also noted. The
degree of damage to the myocardium was
dose related, being less severe for rats
given 3 injections of 30 or 45 mg/M2 at
14 day intervals than for those given 60
mg/M2 on this intermittent schedule.
Animal survival
The relationship between animal sur-
vival and the interval separating succes-
sive doses ofAdr was examined in tumour-
free rats and these data are shown in Fig.
7. The i.p. route was utilized for this
experiment, and survival was determined
21 days after the last injection. All rats
survived a single 60 mg/M2 dose of Adr.
Two 60 mg/M2 doses given together were
uniformly fatal. Intervals between 2
injections of 4 and 8 days gave increasing
survivals. Deaths were most frequent
during the 4-6-day period immediately
after the second injection. Fluid accumula-
tion in both the pleural and peritoneal
cavities was commonly seen at autopsy.
When the interval was 12 or 16 days, 80%
of the rats were alive 21 days after the
second injection. Three 60 mg/M2 injec-
tions at 14-day intervals gave a survival
of 60%, which improved to 100% when
the individual doses were reduced to 45
or 30 mg/M2.
Although TdR incorporation remained
suppressed during recovery of marrow
DNA content after treatment with Adr
(Fig. 4B) injection of the proliferation-
dependent agent FU during this recovery
period proved fatal. For doses of 900 mg/
m2 (150 mg/kg) FU at 7 or 11-day inter-
vals after 60 mg/M2 Adr, 21-day survival
was 0 and 700, respectively. Simultan-
eous administration of the 2 agents gave
a survival of 60%. Total tibial DNA, not
3H-TdR incorporation, is the valid indi-
cator of tolerance for a second treatment
when Adr is the first agent.
Intestinal adhesions occur after Adr is
given i.p. However, this does not com-
promise the validity of the acute-survival
data in Fig. 7 since deaths related to
intestinal adhesions begin to occur only
after 6 weeks. These deaths can be avoided
by using the i.v. or s.c. routes.
Another complication which can affect
long-term toxicity data, and is indepen-
dent of route of administration, is an
effect of cytotoxic drugs on the continu-
ously growing rodent incisor teeth. Zajicek
(1976) has described the rodent incisor-
tooth proliferon as the site of 5 cell
populations proliferating in harmony.
Drugs such as cyclophosphamide (Vahl-
sing, 1975), FU (Hopkins, unpublished)
and Adr perturb these populations, with
the result that the incisors become over-
grown and the rat cannot eat a pelleted
diet. Clipping of the teeth and feeding
powdered diet will prevent death from
starvation. It is important that animal
mortality from overgrown teeth be care-
fully eliminated from toxicity data since
this is not a factor in the clinical use of
these drugs.
DISCUSSION
Adriamycin binds to DNA, and this is
believed to be responsible for its cytotoxic
effects, although the exact mechanism
remains unknown. Synthesis of both RNA
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and DNA is inhibited by the drug for in
vitro cell cultures (Kim and Kim, 1972)
and more recently, single and double DNA-
strand breaks have been seen after treat-
ment of intact cells with Adr (Byfield et
al., 1977). Others have noted the similar,
but not identical, effects of Adr and radi-
ation on cells (Belli and Piro, 1977) and
the possible involvement of ribosomal
RNA synthesis (Clarkson and Humphrey,
1977).
The changes in tumour morphology and
quantitative changes in tumour kinetics
after Adr described here may be compared
with changes in the same solid-tumour
model after an equally effective dose of
the proliferation-dependent cancer-
chemotherapeutic agent FU. In studies
not detailed here, we found no significant,
differences in mean tumour volumes of
animals given 900 mg/M2 (150 mg/kg) FU
or 60 mg/M2 Adr over a period of 16 days
after treatment. The dose of Adr used in
the present study is therefore equivalent
to that of 5-FU (900 mg/M2) in previous
studies, with respect to total perturbation
of tumour growth. The TdR labelling
index was above control values 2 days
after Adr administration. This returned to
control values by Day 4 and remained
below the control unitl Day 16. The rate
of DNA synthesis was also elevated on
Day 2 but depressed from Day 4 until
Day 16. The elevation of both the DNA
specific activity and labelling index on
Day 2 suggests a redistribution of cells
within the cell cycle, with an increased
proportion of cells in the "S" period, as
occurs with FU (Kovacs et al., 1975). The
depression of both DNA specific activity
and labelling indices between Day 4 and
Day 16 could be the result of the direct
effects of Adr on DNA synthesis, as well
as a reduction of S-phase cells. Clarkson
and Humphrey (1977) reported that
Chinese hamster ovary cells treated in
mid-S phase showed a dose-dependent
progression delay which was also reflected
in the rates of DNA replication in the
subsequent S phase. For hepatoma 3924A,
the percentage of labelled cells remain
high up to 1 week after FU administration
(Kovacs et al., 1975).
There are 2 other major changes which
occur after FU which were virtually absent
in the Adr treated tumours: within 48 h
after treatment with 900 mg/M2 FU, there
was a gradual decrease in DNA concen-
tration of the treated tumours. By 7-8
days after treatment, DNA concentration
reached a nadir, and gradual restoration
to the DNA concentration observed for
untreated tumours occurred over the next
2-week period. This reduction of DNA/g
tumour to 700° of that for untreated
tumours reflects cell death and eventual
removal of dead cells beyond the cell loss
normal for growing tumours. Since
protein/g tumour was not affected by
treatment with FU, changes in water
content cannot be responsible for the
decrease in DNA concentration. The DNA
concentration in the Adr-treated tumours
remained unchanged over the entire 22-
day period of the study.
The tissue composition of untreated
tumours remains relatively constant, at
51% tumour, 18o% necrotic, 26% con-
nective and 500 blood, for the range of
tumour volumes used in both the FU and
Adr studies. Tissue composition after
treatment with 900 mg/M2 FU, showed
that the relative number of tumour cells
were reduced to a minimum of 5000 of
untreated-tumour values 48 h after treat-
ment. Concomitantly, increases in both
necrotic and connective tissue were found
over this 48 h period. The relative tissue
composition was restored to untreated
values by 7 days. Little or no pathological
changes were observed in the tumour dur-
ing this period after Adr.
The lack of pathological changes and
changes in DNA concentration in the
tumours after Adr indicates that the
cellular responses are more gradual than
with FU. The results of the 2 studies
suggest that the proliferation-dependent
agent FU causes an abrupt and well-
defined sequence of changes in tumour
morphology and kinetics, whereas Adr
fails to elicit these abrupt and well-
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defined changes. However, the end results
on the perturbations of tumour growth
and the reduction in tumour volume 11
days after the 2 agents are comparable.
The depressed peripheral WBC counts
after 60 mg/M2 Adr were 60-70% of
controls, compared to 50% of controls for
the 900 mg/M2 dose of FU (Hopkins and
Looney, 1978). The total tibial DNA con-
tent has been used as an index of marrow
reserve. There was a loss of 60% of the
marrow after 60 mg/M2 ofAdr and of90%o
after 900 mg/M2 of FU. This dose of FU
which produces an effect on tumour
growth comparable to 60 mg/M2 Adr,
causes a much greater depression of the
marrow. However, the more pronounced
effect of FU upon marrow is not reflected
in the decrease in peripheral WBC
counts.
The survival studies with 2 injections of
Adr separated by various intervals of time
were comparable to survival studies after
FU. Both studies show that giving the
second dose ofeither agent prior to 11 days
results in varying degrees of animal
mortality. Giving the second dose of
either agent 11 days or more after the first
allows the animal to survive. These
comparable recovery kinetics after 2
cancer-chemotherapy agents with different
mechanisms of action, indicate that this
phenomenon is primarily related to the
recovery kinetics of the haematopoietic
system. The recovery of the gastrointes-
tinal mucosa occurs prior to marrow for
either drug. These studies indicate that
recovery of the haematopoietic system is
one factor to be considered in the design
of protocols using Adr.
On the basis of both clinical and
experimental studies (Lenaz and Page,
1976) the heart is considered to be the
dose-limiting organ for accumulated toxi-
city for Adr. Cardiac dysfunction appears
to be a factor in the early deaths reported
here after a single dose of Adr of 120 mg/
M2 or 2 divided doses of 60 mg/M2 given
4 or 8 days after the first. Accumulation
of fluid was seen in both the pleural and
peritoneal cavities at autopsy, suggesting
congestive heart failure. However, no
specific pathological changes were noted
in hearts of animals given 60 mg/M2 of
Adr 2-21 days prior to sacrifice. Studies
over a 14-week period demonstrated
cardiac damage similar to that seen by
others in the rat (Mettler et al., 1977) and
other species. Vacuoles within mycoardial
cells and oedema were prominent after
this long interval. In addition, non-
specific changes such as foci of myocardial
cell degeneration, occasionally seen in
both treated and control rats 2-21 days
from start of experiment, were more
numerous and prominent in the 14-week
animals.
The biochemical results appear to sub-
stantiate the pathological findings of
slowly increasing cardiac damage over
long periods of time. The increased incor-
poration of DNA precursors into heart
DNA is believed to occur mostly in the
endothelial cells of the capillaries and in
the mitochondria of myocardal fibres
(Lenaz and Page, 1976). Adr induces
extensive damage to DNA in cell cultures
(Byfield et al., 1977). The continuous and
long-term increased specific activity in
heart DNA could also be related to repair
of this damage. These studies on depres-
sion of DNA synthesis in the rat after a
large single dose of Adr are comparable to
the findings in the mouse (Young et al.,
1975). The maximum depression of DNA-
synthesis occurs between 3 and 6 days in
both the rat and mouse, with the DNA
synthetic rate returning to control level
by Day 9 in the rat. Recovery data are not
available for the mouse. The rate of DNA
synthesis in the rat heart after both FU
(900 mg /m2) and Adr (60 mg/M2) in-
creased to values above controls on Day 11
but returned to control levels by Day 18.
The long-term studies showed elevated
rates of heart DNA synthesis in rats 3, 8
and 12 weeks after a large single dose of
Adr (60 mg /m2) whether i.v., s.c., or i.p.
(Table I). If this long-term increase in
specific activity of heart DNA is associa-
ted with repair, it would reinforce the
pathological observation that cardiac
10131014 H. A. HOPKINS EP AL.
damage is the final stage of a long-term
process.
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